Oral simvastatin treatment in relapsing-remitting multiple sclerosis
T Vollmer, L Key, V Durkalski, W Tyor, J Corboy… - The Lancet, 2004 - thelancet.com
T Vollmer, L Key, V Durkalski, W Tyor, J Corboy, S Markovic-Plese, J Preiningerova, M Rizzo…
The Lancet, 2004•thelancet.comMany drugs have been approved for relapsing forms of multiple sclerosis but are only partly
effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin
(80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of
gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the
mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-
enhancing lesions declined by 44%,(p< 0· 0001) and 41%(p= 0· 0018), respectively …
effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin
(80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of
gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the
mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-
enhancing lesions declined by 44%,(p< 0· 0001) and 41%(p= 0· 0018), respectively …
Summary
Many drugs have been approved for relapsing forms of multiple sclerosis but are only partly effective, are injected, and are expensive. We aimed to investigate use of of oral simvastatin (80 mg) in 30 individuals with relapsing-remitting multiple sclerosis. The mean number of gadolinium-enhancing lesions at months 4, 5, and 6 of treatment was compared with the mean number of lesions noted on pretreatment brain MRI scans. Number and volume of Gd-enhancing lesions declined by 44%, (p<0·0001) and 41% (p=0·0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability.
thelancet.com